⌕
Halozyme Therapeutics · HALO · Nasdaq
Tenet 71 · Solid
Compare
$95.97−0.55%At closeTenet 71 · Solid
$95.97−0.53 (−0.55%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Halozyme Therapeutics (HALO) Stock

Halozyme Therapeutics (HALO) closed at $95.97 on Nov 17, 2026; its Tenet Score is 71 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

14 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$95.97
Nov 17, 2026
Market cap
$11.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
24.4×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
61.23 – 134.00
low → high · as of close, Nov 16, 2026
Tenet Score
71/100
Solid · 340 Healthcare peers

Industry: Drugs

Halozyme Therapeutics Inc. scores 71/100. Solid. Strongest on growth and quality, trading at 24× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
71/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
67
Quality
71
Health
58
Growth
87

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityBHealthCGrowthBMomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
6.1×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
33.6%
fiscal 2025, before interest and tax
Net margin
26.9%
TTM through Sep 30, 2026
Current ratio
3.88
Sep 30, 2026 balance sheet
Net debt / EBITDA
2.7×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Halozyme Therapeutics Inc.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 222 US ETFs · top wrappers by weightSee all ETFs holding HALO →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Halozyme Therapeutics in?

Halozyme Therapeutics is in the Healthcare sector and the Drugs industry.

What is Halozyme Therapeutics' Tenet Score?

Halozyme Therapeutics' Tenet Score is 71 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.